[THE INVESTOR] Green Cross Lab Cell said Nov. 23 it has been granted a US patent for a cultivating method for natural killer cells that are known to recognize and attack tumors.
The intellectual property is involved with a method for culturing and expanding natural killer cells and its cryopreservation.
Natural killer cells, a component of innate immune system, play a major role in the host-rejection of both tumors and virally infected cells.
“Large-scale culture and cryopreservation technologies are core tasks for the commercialization of natural killer cells as they are difficult to obtain in sufficient quantities due to its short activation period,” the company said.
Prior to the patent issued by the United States Patent and Trademarks Office, the technology was recognized by European and Japanese authorities.
By using the proprietary method, the company is developing a natural killer-based oncology drug MG4101, which is undergoing phase 2 clinical trials to treat liver cancer.
By Park Han-na (firstname.lastname@example.org)